Abbott Laboratories lowered its full-year profit forecast for 2026, citing costs related to a recent acquisition and disappointing sales during what the company described as a milder-than-expected flu season.

The healthcare company's shares fell following the announcement, as investors reacted to the reduced earnings outlook. Abbott attributed the forecast revision to financial impacts from its acquisition of Exact Sciences assets.

The company reported that the weaker flu season contributed to lower sales in its recent quarter. Flu season severity typically affects demand for Abbott's diagnostic tests and other healthcare products, as reduced illness rates lead to fewer medical visits and testing procedures.

Abbott's decision to trim its 2026 profit forecast reflects both the integration costs associated with the Exact deal and the company's assessment that seasonal illness patterns negatively impacted its financial performance. The acquisition-related expenses are expected to continue affecting the company's earnings profile through 2026.

The forecast adjustment comes as healthcare companies navigate varying seasonal disease patterns that can significantly impact quarterly and annual financial results, particularly for companies with substantial diagnostic testing operations.